CTLA4 and metastatic melanoma: Starting with the approval of the CTLA-4–targeting ICI ipilimumab for metastatic melanoma in 2011, the subsequent decade of immunotherapy has introduced several antibody-based, cell-based, and vaccine-based treatment options for patients with cancer, with many more options expected in the next 5 to 10 years (43).